Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.

Topakian R, Zimprich F, Iglseder S, Embacher N, Guger M, Stieglbauer K, Langenscheidt D, Rath J, Quasthoff S, Simschitz P, Wanschitz J, Windisch D, Müller P, Oel D, Schustereder G, Einsiedler S, Eggers C, Löscher W.

J Neurol. 2019 Mar;266(3):699-706. doi: 10.1007/s00415-019-09191-6. Epub 2019 Jan 16.

PMID:
30649616
2.

Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatment.

Löscher WN, Oberreiter EM, Erdler M, Quasthoff S, Culea V, Berek K, Embacher N, Grinzinger S, Hess I, Höger FS, Horlings CGC, Huemer M, Jecel J, Kleindienst W, Laich E, Müller P, Oel D, Örtl W, Lenzenweger E, Rath J, Stadler K, Stieglbauer K, Thaler-Wolf C, Wanschitz J, Zimprich F, Cetin H, Topakian R.

J Neurol. 2018 Dec;265(12):2834-2840. doi: 10.1007/s00415-018-9071-9. Epub 2018 Sep 26.

3.

Reply: Elevated Cardiac Troponin T in Skeletal Myopathies: Skeletal TnT Cross-Reactivity and/or Cardiac TnT Expression?

Schmid J, Birner-Grünberger R, Quasthoff S, Binder JS, Rainer PP.

J Am Coll Cardiol. 2018 Jul 17;72(3):349-350. doi: 10.1016/j.jacc.2018.05.019. Epub 2018 Jul 9. No abstract available.

4.

Elevated Cardiac Troponin T in Patients With Skeletal Myopathies.

Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger B, Asslaber M, Radl R, Beer M, Polacin M, Mair J, Szolar D, Berghold A, Quasthoff S, Binder JS, Rainer PP.

J Am Coll Cardiol. 2018 Apr 10;71(14):1540-1549. doi: 10.1016/j.jacc.2018.01.070.

5.

Pompe disease in Austria: clinical, genetic and epidemiological aspects.

Löscher WN, Huemer M, Stulnig TM, Simschitz P, Iglseder S, Eggers C, Moser H, Möslinger D, Freilinger M, Lagler F, Grinzinger S, Reichhardt M, Bittner RE, Schmidt WM, Lex U, Brunner-Krainz M, Quasthoff S, Wanschitz JV.

J Neurol. 2018 Jan;265(1):159-164. doi: 10.1007/s00415-017-8686-6. Epub 2017 Nov 27.

6.

[Migraine prophylaxis with trigger point therapy and lymphatic drainage : A pilot study].

Yedikardachian D, Quasthoff S, Lechner AT, Giuliani A, Fazekas F.

Wien Med Wochenschr. 2017 Nov;167(15-16):359-367. doi: 10.1007/s10354-017-0588-9. Epub 2017 Aug 2. German.

PMID:
28770409
7.

Multimodal assessment of white matter tracts in amyotrophic lateral sclerosis.

Borsodi F, Culea V, Langkammer C, Khalil M, Pirpamer L, Quasthoff S, Enzinger C, Schmidt R, Fazekas F, Ropele S.

PLoS One. 2017 Jun 2;12(6):e0178371. doi: 10.1371/journal.pone.0178371. eCollection 2017.

8.

The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis.

Robier C, Amouzadeh-Ghadikolai O, Bregant C, Diez J, Melinz K, Quehenberger F, Quasthoff S.

Int J Lab Hematol. 2017 Oct;39(5):469-474. doi: 10.1111/ijlh.12662. Epub 2017 May 8.

PMID:
28481019
9.

Causally treatable, hereditary neuropathies in Fabry's disease, transthyretin-related familial amyloidosis, and Pompe's disease.

Finsterer J, Wanschitz J, Quasthoff S, Iglseder S, Löscher W, Grisold W.

Acta Neurol Scand. 2017 Dec;136(6):558-569. doi: 10.1111/ane.12758. Epub 2017 Mar 12. Review.

PMID:
28295152
10.

Secondary myopathy due to systemic diseases.

Finsterer J, Löscher WN, Wanschitz J, Quasthoff S, Grisold W.

Acta Neurol Scand. 2016 Dec;134(6):388-402. doi: 10.1111/ane.12576. Epub 2016 Feb 25. Review.

PMID:
26915593
11.

Clinical-Pathological Conference Series from the Medical University of Graz : Case No 160: 33-year-old woman with tetraparesis on Easter Sunday.

Fabian E, Schiller D, Tomaschitz A, Langner C, Pilz S, Quasthoff S, Raggam RB, Schoefl R, Krejs GJ.

Wien Klin Wochenschr. 2016 Oct;128(19-20):719-727. Epub 2016 Sep 28. No abstract available.

12.

The Value of Median Nerve Sonography as a Predictor for Short- and Long-Term Clinical Outcomes in Patients with Carpal Tunnel Syndrome: A Prospective Long-Term Follow-Up Study.

Marschall A, Ficjian A, Stradner MH, Husic R, Zauner D, Seel W, Simmet NE, Klammer A, Heizer P, Brickmann K, Gretler J, Fürst-Moazedi FC, Thonhofer R, Hermann J, Graninger WB, Quasthoff S, Dejaco C.

PLoS One. 2016 Sep 23;11(9):e0162288. doi: 10.1371/journal.pone.0162288. eCollection 2016.

13.

Iatrogenic lesions of peripheral nerves.

Löscher WN, Wanschitz J, Iglseder S, Vass A, Grinzinger S, Pöschl P, Grisold W, Ninkovic M, Antoniadis G, Pedro MT, König R, Quasthoff S, Oder W, Finsterer J.

Acta Neurol Scand. 2015 Nov;132(5):291-303. doi: 10.1111/ane.12407. Epub 2015 Apr 16. Review.

PMID:
25882317
14.

The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.

Robier C, Amouzadeh-Ghadikolai O, Bregant C, Diez J, Melinz K, Neubauer M, Quasthoff S.

Mult Scler. 2014 Aug;20(9):1269-72. doi: 10.1177/1352458514521307. Epub 2014 Feb 3.

PMID:
24493472
15.

Response to: 'Paying attention to carpal tunnel contents lesions: ultrasound for evaluation of carpal tunnel syndrome' by zhu and Liu.

Dejaco C, Stradner M, Zauner D, Seel W, Simmet NE, Klammer A, Heitzer P, Brickmann K, Gretler J, Fürst-Moazedi F, Thonhofer R, Husic R, Hermann J, Graninger WB, Quasthoff S.

Ann Rheum Dis. 2014 Apr;73(4):e17. doi: 10.1136/annrheumdis-2013-205038. Epub 2014 Jan 9. No abstract available.

PMID:
24406545
16.

Hirayama disease in Austria.

Finsterer J, Löscher W, Wanschitz J, Baumann M, Quasthoff S, Grisold W.

Joint Bone Spine. 2013 Oct;80(5):503-7. doi: 10.1016/j.jbspin.2012.10.013. Epub 2012 Dec 10.

PMID:
23237996
17.

Ultrasound for diagnosis of carpal tunnel syndrome: comparison of different methods to determine median nerve volume and value of power Doppler sonography.

Dejaco C, Stradner M, Zauner D, Seel W, Simmet NE, Klammer A, Heitzer P, Brickmann K, Gretler J, Fürst-Moazedi FC, Thonhofer R, Husic R, Hermann J, Graninger WB, Quasthoff S.

Ann Rheum Dis. 2013 Dec;72(12):1934-9. doi: 10.1136/annrheumdis-2012-202328. Epub 2012 Dec 4.

PMID:
23212030
18.

Spongious hypertrophic cardiomyopathy in patients with mutations in the four-and-a-half LIM domain 1 gene.

Binder JS, Weidemann F, Schoser B, Niemann M, Machann W, Beer M, Plank G, Schmidt A, Bisping E, Poparic I, Lafer I, Stojakovic T, Quasthoff S, Vincent JB, Rienmueller R, Speicher MR, Berghold A, Pieske B, Windpassinger C.

Circ Cardiovasc Genet. 2012 Oct 1;5(5):490-502. doi: 10.1161/CIRCGENETICS.111.962332. Epub 2012 Aug 25.

PMID:
22923418
19.

Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance.

Finsterer J, Löscher W, Quasthoff S, Wanschitz J, Auer-Grumbach M, Stevanin G.

J Neurol Sci. 2012 Jul 15;318(1-2):1-18. doi: 10.1016/j.jns.2012.03.025. Epub 2012 May 1. Review.

PMID:
22554690
20.

Four and a half LIM protein 1C (FHL1C): a binding partner for voltage-gated potassium channel K(v1.5).

Poparic I, Schreibmayer W, Schoser B, Desoye G, Gorischek A, Miedl H, Hochmeister S, Binder J, Quasthoff S, Wagner K, Windpassinger C, Malle E.

PLoS One. 2011;6(10):e26524. doi: 10.1371/journal.pone.0026524. Epub 2011 Oct 28.

21.
22.

Mapping of iron deposition in conjunction with assessment of nerve fiber tract integrity in amyotrophic lateral sclerosis.

Langkammer C, Enzinger C, Quasthoff S, Grafenauer P, Soellinger M, Fazekas F, Ropele S.

J Magn Reson Imaging. 2010 Jun;31(6):1339-45. doi: 10.1002/jmri.22185.

PMID:
20512885
23.

Consequences of mutations within the C terminus of the FHL1 gene.

Schoser B, Goebel HH, Janisch I, Quasthoff S, Rother J, Bergmann M, Müller-Felber W, Windpassinger C.

Neurology. 2009 Aug 18;73(7):543-51. doi: 10.1212/WNL.0b013e3181b2a4b3.

PMID:
19687455
24.

Wolff-Parkinson-White syndrome as initial manifestation of Becker muscular dystrophy.

Finsterer J, Stöllberger C, Quasthoff S.

Herz. 2008 Jun;33(4):307-10. doi: 10.1007/s00059-008-3023-6.

PMID:
18581080
25.

Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects.

Quasthoff S, Möckel C, Zieglgänsberger W, Schreibmayer W.

CNS Neurosci Ther. 2008 Summer;14(2):107-19. doi: 10.1111/j.1527-3458.2008.00044.x. Review.

26.

An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1.

Windpassinger C, Schoser B, Straub V, Hochmeister S, Noor A, Lohberger B, Farra N, Petek E, Schwarzbraun T, Ofner L, Löscher WN, Wagner K, Lochmüller H, Vincent JB, Quasthoff S.

Am J Hum Genet. 2008 Jan;82(1):88-99. doi: 10.1016/j.ajhg.2007.09.004.

27.

Itch, skin lesions--and a stiff neck.

Wiesner T, Leinweber B, Quasthoff S, Unger B, Komericki P, Hoedl S, Kerl H.

Lancet. 2007 Jul 21;370(9583):290. doi: 10.1016/S0140-6736(07)61131-3. No abstract available.

PMID:
17658400
28.

The TTX metabolite 4,9-anhydro-TTX is a highly specific blocker of the Na(v1.6) voltage-dependent sodium channel.

Rosker C, Lohberger B, Hofer D, Steinecker B, Quasthoff S, Schreibmayer W.

Am J Physiol Cell Physiol. 2007 Aug;293(2):C783-9. Epub 2007 May 23.

29.

Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study.

von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F, Obermeier F, Erdmann J, Schmelz R, Quasthoff S, Adelsberger H, Bredenkamp R, Schmid RM, Lersch C.

Invest New Drugs. 2007 Apr;25(2):173-80. Epub 2006 Sep 13.

PMID:
16983507
30.

A comparative study of the action of tolperisone on seven different voltage dependent sodium channel isoforms.

Hofer D, Lohberger B, Steinecker B, Schmidt K, Quasthoff S, Schreibmayer W.

Eur J Pharmacol. 2006 May 24;538(1-3):5-14. Epub 2006 Mar 21.

PMID:
16650844
31.

[Evidence-based therapy of painful neuropathies in the primary care practice].

Quasthoff S.

MMW Fortschr Med. 2005 May 17;147 Spec No 2:78-82. German.

PMID:
15968878
32.

Morvan's syndrome: clinical, laboratory, and in vitro electrophysiological studies.

Löscher WN, Wanschitz J, Reiners K, Quasthoff S.

Muscle Nerve. 2004 Aug;30(2):157-63.

PMID:
15266630
33.

No blocking effects of the pentapeptide QYNAD on Na+ channel subtypes expressed in Xenopus oocytes or action potential conduction in isolated rat sural nerve.

Quasthoff S, Pojer C, Mori A, Hofer D, Liebmann P, Kieseier BC, Schreibmayer W.

Neurosci Lett. 2003 Dec 4;352(2):93-6.

PMID:
14625031
34.

Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.

Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde E, Quasthoff S, Grosskreutz J, Adelsberger H.

Clin Colorectal Cancer. 2002 May;2(1):54-8.

PMID:
12453338
35.

Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

Gamelin E, Gamelin L, Bossi L, Quasthoff S.

Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33. Review.

PMID:
12422305
36.

Chemotherapy-induced peripheral neuropathy.

Quasthoff S, Hartung HP.

J Neurol. 2002 Jan;249(1):9-17. Review.

PMID:
11954874
37.

[Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].

Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C.

Dtsch Med Wochenschr. 2002 Jan 18;127(3):78-82. German.

PMID:
11797144
38.

[Nerve growth factor (NGF) in treatment of diabetic polyneuropathy. One hope less?].

Quasthoff S, Hartung HP.

Nervenarzt. 2001 Jun;72(6):456-9. German.

PMID:
11433707
39.

Expression of messenger RNA of the cardiac isoforms of troponin T and I in myopathic skeletal muscle.

Messner B, Baum H, Fischer P, Quasthoff S, Neumeier D.

Am J Clin Pathol. 2000 Oct;114(4):544-9. Erratum in: Am J Clin Pathol 2000 Dec;114(6):986.

PMID:
11026100
40.

The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.

Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C.

Eur J Pharmacol. 2000 Oct 6;406(1):25-32.

PMID:
11011028
41.

X-linked dominant Charcot-Marie-Tooth neuropathy: clinical, electrophysiological, and morphological phenotype in four families with different connexin32 mutations(1).

Senderek J, Hermanns B, Bergmann C, Boroojerdi B, Bajbouj M, Hungs M, Ramaekers VT, Quasthoff S, Karch D, Schröder JM.

J Neurol Sci. 1999 Aug 15;167(2):90-101.

PMID:
10521546
42.
43.

The role of axonal ion conductances in diabetic neuropathy: a review.

Quasthoff S.

Muscle Nerve. 1998 Oct;21(10):1246-55. Review.

PMID:
9736052
45.

[Regional distribution of predisposition to maligant hyperthermia in Germany: tate in 1997].

Hartung E, Anetseder M, Olthoff D, Deutrich C, Lehmann-Horn F, Baur C, Mortier W, Tzanova I, Doetsch S, Quasthoff S, Hofmann M, Schwefler B, Jantzen JP, Wappler F, Scholz J.

Anasthesiol Intensivmed Notfallmed Schmerzther. 1998 Apr;33(4):238-43. German.

PMID:
9617422
46.

Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.

Thödtmann F, Theiss F, Kemmerich M, Heinrich B, Laubenbacher C, Quasthoff S, Kau R, Herzog M, Diergarten K, Hanauske AR.

Ann Oncol. 1998 Mar;9(3):335-7.

PMID:
9602270
47.

X-linked dominant Charcot-Marie-Tooth disease: nerve biopsies allow morphological evaluation and detection of connexin32 mutations (Arg15Trp, Arg22Gln).

Senderek J, Bergmann C, Quasthoff S, Ramaekers VT, Schröder JM.

Acta Neuropathol. 1998 May;95(5):443-9.

PMID:
9600589
48.
49.

Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study.

Schilling T, Heinrich B, Kau R, Herzog M, Quasthoff S, Diergarten K, Rastetter J, Hanauske AR.

Oncology. 1997 Mar-Apr;54(2):89-95.

PMID:
9075777
50.

Function of the hyperpolarization-activated inward rectification in nonmyelinated peripheral rat and human axons.

Grafe P, Quasthoff S, Grosskreutz J, Alzheimer C.

J Neurophysiol. 1997 Jan;77(1):421-6.

Supplemental Content

Loading ...
Support Center